Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia.
Luna A, Pérez-Lamas L, Boque C, Giraldo P, Xicoy B, Ruiz Nuño C, Vega MM, Alvarez-Larrán A, Salamanca A, García-Noblejas A, Vall-Llovera F, Villalon L, De Las Heras N, Ramila E, Pérez-Encinas M, Cuevas B, Perez-Lopez R, Sanchez-Guijo F, Jiménez-Velasco A, Lakhwani S, Casado LF, Rosell A, Escola A, Fernández MJ, Garcia-Hernandez C, Cervero C, Mora E, Sagüés M, Suarez-Varela S, Vélez P, Carrascosa Mastell P, Bitaube RF, Serrano L, Cortes M, Vera Goñi JA, Steegmann JL, de Soria VGG, Alonso-Dominguez JM, Araujo MC, Coll AP, Hernandez-Boluda JC, García-Gutiérrez V. Luna A, et al. Among authors: lakhwani s. Ann Hematol. 2022 Oct;101(10):2263-2270. doi: 10.1007/s00277-022-04932-6. Epub 2022 Aug 23. Ann Hematol. 2022. PMID: 35997804 Free PMC article.
Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice.
Garcia-Gutiérrez V, Luna A, Alonso-Dominguez JM, Estrada N, Boque C, Xicoy B, Giraldo P, Angona A, Alvarez-Larrán A, Sanchez-Guijo F, Ramírez MJ, Mora E, Vélez P, Rosell A, Colorado Araujo M, Cuevas B, Sagüés M, Cortes M, Encinas MP, Casado Montero LF, Moreno Vega M, Serrano L, Gomez V, Garcia-Hernandez C, Lakhwani S, Paz Coll A, de Paz R, Suarez-Varela S, Fernandez-Ruiz A, Perez Lopez R, Ortiz-Fernández A, Jiménez-Velasco A, Steegmann-Olmedillas JL, Hernández-Boluda JC. Garcia-Gutiérrez V, et al. Among authors: lakhwani s. Blood Cancer J. 2021 Feb 9;11(2):16. doi: 10.1038/s41408-021-00420-8. Blood Cancer J. 2021. PMID: 33563899 Free PMC article. No abstract available.
Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors.
Pérez-Lamas L, Luna A, Boque C, Xicoy B, Giraldo P, Pérez López R, Ruiz Nuño C, De Las Heras N, Mora Casterá E, López Marín J, Segura Díaz A, Gómez V, Vélez Tenza P, Sierra Pacho M, Vera Goñi JA, Moreno Vega M, Alvarez-Larrán A, Cortés M, Pérez Encinas M, Carrascosa Mastell P, Angona A, Rosell A, Lakhwani S, Colorado M, Ramila E, Cervero C, Cuevas B, Villalón Blanco L, de Paz R, Paz Coll A, Fernández MJ, Felipe Casado L, Alonso-Domínguez JM, Anguita Arance MM, Salamanca Cuenca A, Jiménez-Velasco A, Prendes SO, Santaliestra M, Lis Chulvi MJ, Hernández-Boluda JC, García-Gutiérrez V. Pérez-Lamas L, et al. Among authors: lakhwani s. Cancers (Basel). 2023 Feb 7;15(4):1045. doi: 10.3390/cancers15041045. Cancers (Basel). 2023. PMID: 36831388 Free PMC article.
Treatment with daratumumab in patients with relapsed/refractory AL amyloidosis: a multicentric retrospective study and review of the literature.
Lecumberri R, Krsnik I, Askari E, Sirvent M, González-Pérez MS, Escalante F, Pradillo V, Tamariz LE, Cánovas V, Alegre A, Gironella M, González-García ME, Infante MS, Lakhwani S, Martínez-Bilbao C, Dourdil V, Ramírez-Payer Á, Sarrá J, Cibeira MT. Lecumberri R, et al. Among authors: lakhwani s. Amyloid. 2020 Sep;27(3):163-167. doi: 10.1080/13506129.2020.1730791. Epub 2020 Feb 28. Amyloid. 2020. PMID: 32106714 Clinical Trial.
Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.
Lakhwani S, Rosiñol L, Puig N, Pico-Picos MA, Medina-González L, Martínez-López J, Paiva B, Cedena MT, Oriol A, Ríos-Tamayo R, Blanchard MJ, Jarque I, Bargay J, Moraleda JM, Carrillo-Cruz E, Sureda A, Krsnik I, González E, Casado LF, Martí JM, Encinas C, De Arriba F, Palomera L, Sampol A, González-Montes Y, Motlló C, De La Cruz J, Alonso R, Mateos MV, Bladé J, Lahuerta JJ, San-Miguel J, Hernández MT. Lakhwani S, et al. Haematologica. 2024 Jun 1;109(6):1909-1917. doi: 10.3324/haematol.2023.284154. Haematologica. 2024. PMID: 38031761 Free PMC article. Clinical Trial.
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Gibbs S, Mollee P, Venner CP, Lu J, Schönland S, Gatt ME, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman AJ, Goodman SA, Zonder JA, Lam S, Song K, Hansen T, Manier S, Roeloffzen W, Jamroziak K, Kwok F, Shimazaki C, Kim JS, Crusoe E, Ahmadi T, Tran N, Qin X, Vasey SY, Tromp B, Schecter JM, Weiss BM, Zhuang SH, Vermeulen J, Merlini G, Comenzo RL; ANDROMEDA Trial Investigators. Kastritis E, et al. N Engl J Med. 2021 Jul 1;385(1):46-58. doi: 10.1056/NEJMoa2028631. N Engl J Med. 2021. PMID: 34192431 Clinical Trial.
22 results